Current traditional cancer screening is insufficient.
Low Availability
8 in 10
cancer deaths are not covered by conventional screening [1]*
*Only colorectal, cervical, and breast cancer are recommended by public agencies for screening in Singapore and Hong Kong
Low Accuracy
4 in 10
patients encounter false-positives from other tumor marker screening [2]*
*Cumulative risk of 43.1% false positives over 14 screening exams from other tumor marker screening methods including chest radiograph, flexible sigmoidoscopy, CA-125, and transvaginal ultrasonography for women, and chest radiograph, flexible sigmoidoscopy, PSA, and DRE for men.
Early stage is defined as Stage I and II. Late stage is defined as Stage IV.
Earlier cancer detection saves lives
The 5 year survival rate increases by up to 13.5x when detected in the early stage [3].
LucenceINSIGHT is a multi-cancer early detection (MCED)
next-generation sequencing (NGS) blood test that screens for up to 50 cancers with 99% specificity (low false-positives).
The test uses Lucence's mirror barcoding technology to detect ctDNA, ctRNA, and viral DNA. It can then predict tumor location with machine learning.
LucenceINSIGHT does not diagnose cancer. Further confirmatory testing is recommended for positive results.
Available internationally outside the USA.
99%
Specificity [4]
100%
Positive Predictive Value [5]
88%
Tumor Localization Accuracy [4]
LucenceINSIGHT is recommended for patients:
-
aged 40+
-
have elevated risk of cancer (due to family history, diet, and lifestyle)
Boosted detection with Circulating Tumor RNA (ctRNA) Tumor Markers
12.5% relative increase
in sensitivity
for detection of lung, colon and breast cancer with ctRNA + ctDNA
ctRNA are cancer signals shed into the blood by living cancer cells [6]. LucenceINSIGHT now combines ctDNA and ctRNA analysis to enhance cancer signal detection.
The ctRNA tumor marker boost is useful for screening individuals at high-risk:
-
Family history of lung, colon, or breast cancer
-
Heavy smoker
ctRNA tumor marker boost is included with LucenceINSIGHT 50 and available as an optional add-on for LucenceINSIGHT 5, 7, and 12.
#ctRNA is stable at room temperature for 96 hours. *Sensitivity increase calculated as relative improvement over a ctDNA-only approach, based on an initial training dataset of three cancer types (lung, colon, breast) and independently validated on an internal dataset. Magnitude of increase varies by cancer type. †High-risk = family history of lung, colon, or breast cancer, heavy smoker, and other conditions.
Downloads
Find out which test is right for you.
References:
-
Bray, F. et al. CA Cancer J. Clin. 2024; 74(3): 229-263. Calculated based on colorectal, cervical and breast cancer data.
-
Croswell, J. et al. Ann. Fam. Med. 2009; 7(3): 212–222.
-
Cancer Stat Facts. NIH NCI SEER. Accessed July 28, 2025. https://seer.cancer.gov/statfacts/.
-
Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042. The ctDNA-based LucenceINSIGHT® demonstrated a specificity of 99.0% (310/313 self-declared healthy donors) and an overall sensitivity of 80.9% (233/288 cancer patients). Across the 21 tissue-of-origin classes analyzed, a high confidence prediction could be made in 62.4% (mean 73.6%, range 26.7%-100%) of cases with an overall accuracy of 87.7% (mean 84.9%, range 33.3%-100%).
-
Tucker, S. et al. Ann. Oncol. 2023; 34: S1625-S1626.
-
Stejskal P, et al. Mol Cancer 2023; 22(15).
